Whole Brain Radiotherapy Plus Conventional Boost in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospective Analysis of Overall Survival

Creative Commons License

Kandaz M., Guler O. C., Yazar U., Canyılmaz E., Yoney A.

TURKISH NEUROSURGERY, cilt.29, ss.464-469, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5137/1019-5149.jtn.22896-18.3
  • Dergi Adı: TURKISH NEUROSURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.464-469
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

AIM: To evaluate the clinical characteristics and treatment outcomes of non-small cell lung cancer (NSCLC) patients with brain
metastasis, who were treated by whole brain radiotherapy with a conventional boost at a single institution.
MATERIAL and METHODS: A total of 296 patients diagnosed with NSCLC with brain metastasis and referred to our clinic for
radiotherapy between 2000 and 2017 were included in this retrospective study.
RESULTS: The median age was 60.8 ± 12.1 years, with a range of 21–85 years. The estimated median survival time for all patients
was 7.81 ± 0.66 months (95% CI: 6.52–9.11). The one-year survival, two-year survival and three-year survival rates were 18.8%,
5.8% and 2.9%, respectively. The median survival of patients with solitary brain metastasis who received 45 Gy radiotherapy was
14.70 ± 2.80 months (95% CI: 9.20–20.20). These patients had 6 and 12 months survival rates of 65.4% and 42.6%, respectively.
The median survival time of patients with solitary brain metastasis who received > 45 Gy radiotherapywas 13.86 ± 2.56 months
(95% CI: 8.08–18.02). These patients had 6 and 12 months survival rates of 66.2% and 27.2%, respectively. There was no significant
difference between the two groups (p=0.321). The median survival duration of patients under 65 years was 9.65 ± 1.02 months. The
median survival time of patients aged 65 years and overwas 5.15 ± 0.51 months. There was a statistically significant difference in
the median survival rates between the groups (p<0.001).
CONCLUSION: Patients with solitary metastasis or single metastases tolerated whole brain radiotherapy with a conventional boost.
Although the overall survival rates were numerically better in the high dose RT group, the difference was not statistically significant.
Prospective studies with a larger sample size are needed to consolidate our results.
KEYWORDS: Non-small cell lung cancer, Brain metastases, Radiotherapy